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Abstract  The  prognosis  for  testicular  cancer  is  excellent,  with  a  5-year  survival  rate  greater
than 95%.  Patients  affected  can  therefore  expect  to  be  cured  after  treatment.  Successful  treat-
ment requires  assessment  of  the  condition  at  the  various  stages  of  its  management.  Imaging
plays a  major  role  in  initial  analysis  of  the  lymphatic  extension  and  in  looking  for  metastases.
It is  essential  for  evaluating  the  response  to  treatment  and  during  follow-up  after  treatment.
CT is  the  most  commonly  used  imaging  method  in  this  context,  but  the  role  of  PET  is  currently
developing.  The  purpose  of  this  paper  is  to  review  the  role  of  the  imaging  methods  commonly
used in  the  management  of  testicular  cancer.
© 2012  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Testicular  cancer  accounts  for  1%  of  malignant  tumours  in  men.  It  is  the  commonest  cancer
in  men  between  20  and  40  years  of  age.  It  is  rare  before  the  age  of  15  and  after  50  years
old.  Its  incidence  has  doubled  in  the  last  40  years  to  reach  the  ﬁgure  of  four  to  six/100,000
inhabitants  in  developed  countries  [1].95%  of  testicular  cancers  are  seminomatous  or  non-seminomatous  germ  cell  tumours:
seminomatous  tumours  occur  above  all  in  men  between  the  ages  of  35  and  45  years
(median  =  38  years),  while  non-seminomatous  tumours  occur  mainly  in  men  between  15
and  35  years  old  (median  =  28  years).
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Boxed  text  1  TNM  classiﬁcation  2002  [6].
T.  Only  pathological  classiﬁcation  is  used  after
orchiectomy.
pTx:  Tumour  cannot  be  assessed  (no  castration).
pT0:  No  tumour  (e.g.  ﬁbrous  scar).
pTis:  Carcinoma  in  situ  (or  intratubular  neoplasia:
ITP).
pT1:  Tumour  limited  to  the  testis  and/or  the
epididymis  without  vascular  or  lymphatic  invasion.  The
lesion  may  inﬁltrate  the  tunica  albuginea  but  not  the
tunica  vaginalis.
pT2:  Tumour  limited  to  the  testis  and/or  the
epididymis  with  vascular  or  lymphatic  invasion,  or
lesion  crossing  the  tunica  albuginea  and  invading  the
tunica  vaginalis.
pT3:  Tumour  inﬁltrating  the  spermatic  cord.
pT4:  Tumour  inﬁltrating  the  wall  of  the  scrotum.
N:  Only  concerns  the  regional  lymph  nodes
(interaortocaval,  paraaortic,  paracaval,  preaortic,
precaval,  retroaortic,  retrocaval).  Other  lymph  node
areas  are  considered  metastatic  zones  (N  =  pN).
Nx:  Lymph  nodes  cannot  be  assessed.
N0:  No  lymph  node  metastasis.
N1:  1  or  more  lymph  nodes  of  less  than  2  cm.
N2:  1  or  more  lymph  nodes  between  2  and  5  cm.
N3:  Lymph  nodes  of  more  than  5  cm.
M:  Distant  metastases.
Mx:  Metastases  cannot  be  assessed.
M0:  No  metastasis.
M1:  Distant  metastases.
M1a:  Non-regional  nodal  or  pulmonary  metastases.
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Despite  its  increasing  incidence,  testicular  cancer  has
become  a  model  of  curable  cancer  over  the  last  20  years,
due  to  the  different  therapeutic  protocols  based  on  surgery
(inguinal  orchiectomy),  radiotherapy,  and  chemotherapy
including  platinum  salts.  The  cure  rate  for  early  stages  is
99%,  and  for  advanced  stages  with  a  good  prognosis,  inter-
mediate  prognosis  and  poor  prognosis,  90%,  75  to  80%  and
50%  respectively  [2].  The  prognosis  depends  on  early  diag-
nosis  and  the  histopathological  type  of  the  tumour.
Imaging  using  ultrasound  examination  of  the  scrotum
plays  a  major  role  in  initial  diagnosis  of  the  tumour.  It  also
has  a  prominent  position  in  staging,  looking  for  lymph  node
or  visceral  metastasis,  in  evaluating  the  response  to  treat-
ment  after  radiotherapy  or  chemotherapy,  and  in  monitoring
treated  patients  for  possible  recurrence.
The  aim  of  this  paper  is  to  clarify  and  justify  the  imag-
ing  examinations  to  be  carried  out  in  the  initial  staging  of
testicular  cancer  and  in  assessment  of  the  tumour  during
treatment  and  post-therapeutic  follow-up.
Imaging examinations to be performed in
staging testicular cancer
Several  classiﬁcations  are  used  in  the  literature  for  the
initial  assessment  of  a  germ  cell  tumour  of  the  testis.
In  imaging,  it  is  recommended  to  apply  the  TNM  interna-
tional  classiﬁcation  criteria,  which  differentiate  between
the  local  tumour  and  lymph  or  haematogenous  extensions
[3—6]  (Boxed  text  1  ).  With  these  TNM  classiﬁcation  crite-
ria,  it  is  possible  to  include  patients  in  one  of  the  four  stages
of  the  AJCC  classiﬁcation  [7]  (Table  1),  which  is  often  used
to  determine  the  prognosis  and  patient  survival,  the  latter
also  being  provided  by  the  International  Germ  Cell  Cancer
Collaborative  Group  (IGCCCG)  classiﬁcation  [2]  (Table  2).
The T stage
In  determining  the  T  stage,  there  is  currently  little  or  no
contribution  from  imaging.  Ultrasound  examination  of  the
scrotum  does  indeed  conﬁrm  the  diagnosis  of  a  solid  intrat-
esticular  tumour  [8,9]  (Fig.  1a),  but  it  does  not  provide
sufﬁciently  reliable  information  to  analyse  the  key  points
Table  1  AJCC  classiﬁcation  [7].
Stage  I  Tumour  limited  to  the  testis
(normal  CT  and  markers)
Stage  I  serological  Tumour  limited  to  the  testis  with
persistence  of  elevated  markers
Stage  II  Subdiaphragmatic  lymph  node
involvement
II  a  <2  cm
II  b  2  to  5  cm
II  c  >5  cm
Stage  III  Supradiaphragmatic  lymph  node
or  pulmonary  or  other  visceral
involvement
This classiﬁcation applies only to testicular germ cell tumours.
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f  the  T  stage:  whether  the  tunica  albuginea,  tunica  vagi-
alis,  epididymis  or  spermatic  cord  are  involved  and  looking
or  vascular  or  lymphatic  emboli  [3—5]. MRI  of  the  testes
eems  to  be  more  efﬁcient  than  ultrasound  for  detecting
nvolvement  of  the  tunica  albuginea,  the  epididymis  and
he  spermatic  cord  [10], but  only  the  histological  analysis
f  the  specimen  after  inguinal  orchiectomy  is  today  taken
nto  account  in  determining  the  T  stage  of  testicular  cancer,
hich  is  thus  always  a  postoperative  pT  stage  [3—5].
he N stage
o  determine  the  N  stage,  it  must  be  remembered  that  the
ymphatic  drainage  of  the  testis  occurs  preferentially  along
he  spermatic  vessels  and  that  the  ﬁrst  lymph  nodes  involved
the  “regional  nodes”)  in  neoplastic  extension  are  in  the
etroperitoneum  at  the  conﬂuence  of  the  spermatic  veins
nd  the  inferior  vena  cava.  In  exploration  of  a left  testicular
ancer,  these  nodes  should  be  sought  under  the  left  renal
ein  near  the  junction  of  the  left  spermatic  vein  (Fig.  1b).
or  a  right  testis,  these  nodes  should  be  sought  in  the  right
aracaval,  precaval  or  interaortocaval  regions  level  with
ertebra  L2  (Fig.  2).  These  retroperitoneal  lymph  node
ites,  satellites  of  the  spermatic  veins,  need  to  be  analysed
s  a  priority  to  determine  the  N  stage.  Beyond  these
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Table  2  International  Germ  Cell  Cancer  Collaborative  Group  (IGCCCG)  classiﬁcation  [2].
Non-seminomatous  tumours  Seminomas
Good  prognosis  Primitive  testicular  or  retroperitoneal
No  extrapulmonary  visceral  metastasis
alphaFP  <  1000  ng/mL  and  HCG  <  5000  IU/L
and  LDH  <  1.5  ×N
All initial  sites  and  no  non-pulmonary
visceral  metastases  and  normal  alphaFPa
Intermediate  prognosis  Primitive  testicular  or  retroperitoneal
No  extrapulmonary  visceral
metastasis  —  Markers  (one  only):
alphaFP  >  or  equal  to  1000
and  <  10,000  ng/mL
HCG  >  or  equal  to  5000  and  <  50,000  IU/mL
LDH  >  or  equal  to  1.5  ×N and  <  10  ×N
All initial  sites  and  presence  of
non-pulmonary  visceral  metastases  and
normal  alphaFPa
Poor  prognosis  Primitive  mediastinal  or  extrapulmonary
visceral  metastasis/metastases  or
alphaFP  >  10,000  ng/mL  or  HCG  >  50,000
IU/mL  or  LDH  >  10  ×  N
a Possibly elevation of total HCG.
Figure 1. Regional adenomegaly of a left testicular seminoma: a: initial assessment — ultrasound of the left part of the scrotum: well-
delimited hypoechoic left testicular mass (arrows). Normal testicular tissue (arrowhead); b: initial assessment — chest/abdomen/pelvis CT
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atellite mass of the left renal vein (arrowheads), displacing the ao
egional  sites,  any  lymph  node  involvement  is  considered
s  metastatic  and  should  be  included  in  the  M  stage.
Unlike  the  T  stage,  current  recommendations  clearly
all  for  imaging  examinations  to  determine  the  N  stage
3—5],  and  more  speciﬁcally,  for  systematically  undertak-
ng  a  chest/abdomen/pelvis  CT  scan  immediately  before  or
fter  orchiectomy.  The  value  of  a  CT  scan  in  this  context
as  reported  in  the  1990s  [11], but  no  recent  papers  have
een  published  on  the  possible  contribution  of  “multislice”
echnology  in  this  indication,  one  of  the  conclusions  of  a
eta-analysis  published  in  2009  [12].
Neoplastic  lymph  node  diffusion  (stage  greater  than  N0)s  conﬁrmed  in  the  scan  if  a  hypertrophied  lymph  node
adenomegaly)  is  found  in  the  retroperitoneum.  The  short
iameter  of  the  lymph  nodes  should  be  the  measurement
onsidered.  Taking  1  cm  as  the  limit,  CT  scan  speciﬁcity
m
n
C
tthe renal pedicles: left latero-aortic retroperitoneal lymph node
nd inferior vena cava to the right (arrow).
s excellent  (100%).  Its  sensitivity,  however,  is  poor  (37%),
s  micrometastases  do  not  cause  lymph  node  hypertrophy
nd  are  therefore  systematically  missed  (the  method’s  false
egatives)  [11].
Differentiation  between  stages  N1,  N2  and  N3  is  however
asy  with  a  CT  scan  once  adenomegalies  have  been  isolated
n  the  retroperitoneum.  If  the  adenomegalies  are  less  than
 cm  in  diameter,  the  stage  is  N1;  between  2  and  5  cm,  it  is
2  and  more  than  5  cm  corresponds  to  stage  N3  [6].
If  we  limit  ourselves  to  simply  analysing  lymph  node
easurements  and  looking  for  adenomegaly,  MRI  performs
imilarly  to  CT  for  detecting  retroperitoneal  lymph  node
etastases.  Indeed,  the  percentage  of  micrometastases
ot  causing  lymph  node  hypertrophy  is  similar  in  MRI  and
T  scans  [13]. A  few  recent  publications  have  reported
he  advantage  of  combining  conventional  MRI  sequences
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Figure 2. Regional adenomegaly of a right testicular seminoma.
Initial assessment — chest/abdomen/pelvis CT scan with injection
of contrast agent: abdominal slice passing through the renal
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tpedicles: interaortocaval retroperitoneal adenomegaly (arrow),
corresponding to a regional lymph node extension of the right tes-
ticular seminoma.
with  injection  of  a  contrast  medium  targeting  lymph  nodes
(USPIO),  so  as  to  be  able  to  analyse  the  lymph  node  content
and  thus  pick  out  micrometastases  [14,15].  This  technique,
employed  above  all  for  prostate  cancer,  is  still  currently  very
little  used,  because  it  is  restricting  for  both  the  patient
and  the  radiology  team.  MRI  is  therefore  only  proposed  in
this  indication  as  a  replacement  for  a  CT  scan,  and  only  in
patients  in  whom  injection  of  an  iodinated  contrast  agent
is  contraindicated  [3,4]. Lymph  node  analysis  is  limited  to
looking  for  adenomegalies.
A  recent  study  by  the  National  Cancer  Research  Institute
Testis  Cancer  Clinical  Studies  group  [16]  evaluated  the
performance  of  18FDG  PET  in  nodal  staging  of  testicular
cancers  with  a  good  prognosis,  chemotherapy  being  offered
to  PET  positive  patients  and  monitoring  to  PET  negative
patients.  Given  a  rate  of  recurrence  in  patients  with
negative  PET  scans  which  was  too  high  (33  patients  out  of
87),  this  study  was  interrupted.  The  sensitivity  of  18FDG
PET  does  not  at  present  seem  to  be  sufﬁcient  to  detect
lymph  node  micrometastases  and  single  out  patients  with
a  low  risk  of  recurrence.  Its  use  is  not  recommended  in  the
initial  staging  of  testicular  cancer.
The M stage
The  M1  stage  consists  of  visceral  metastatic  and  non-regional
lymph  node  involvement  (e.g.  subdiaphragmatic  lymph  node
involvement).  Visceral  metastases,  principally  pulmonary
and  to  a  lesser  extent,  liver,  brain  or  bone,  are  caused
by  the  extension  of  testicular  cancer  via  a  haematogenous
route.  A  CT  scan  is  currently  the  most  precise  and  most  rapid
imaging  method  for  exploring  the  entire  trunk,  looking  for
metastases  in  the  lungs  and  other  target  organs  [3—5]. The
superiority  of  a  CT  scan  of  the  thorax  over  a  chest  X-ray  has
been  demonstrated  in  this  context  [17]. However,  for  semi-
nomatous  tumours  with  a  good  prognosis,  a  CT  scan  of  the
thorax  can  be  replaced  by  an  ordinary  chest  X-ray  [3,4], irra-
diation  from  an  ordinary  chest  X-ray  being  about  40  times
less  than  from  a  CT  scan  of  the  chest  (0.1  mSv  as  against  4
mSv).
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Cerebral  MRI  may  be  proposed  in  addition  to  the
hest/abdomen/pelvis  CT  scan  when  a  secondary  brain
ocalisation  is  suspected  from  clinical  data,  and  systemat-
cally  for  testicular  tumours  with  a  poor  prognosis  [3,4].
ts  performance  in  detecting  brain  metastases  is  superior
o  that  of  a  CT  scan.  A  spinal  MRI  may  also  be  pro-
osed  when  vertebral  metastasis  has  been  shown  on  the  CT
can.
Bone  scintigraphy  using  technetium-99m  labelled  phos-
hate  derivatives  is  recommended  in  patients  when  bone
etastasis  is  suspected  from  clinical  or  laboratory  tests
3,4].  However,  18FDG  PET  is  not  indicated  in  initial  staging
f  testicular  cancer.
maging examinations to be performed for
valuation of metastatic testicular cancer
uring treatment
his  section  deals  exclusively  with  metastatic  testicular
ancer  requiring  treatment  in  addition  to  inguinal  orchiec-
omy.  This  chemotherapeutic  treatment,  including  platinum
alts  (the  BEP  protocol:  bleomycin,  etoposide,  cisplatin)
s  highly  effective  on  nodal  masses  and  visceral  metas-
ases.  The  purpose  of  imaging  is  to  monitor  the  evolution  of
he  metastatic  targets  under  treatment  by  measuring  their
iameter  over  several  consecutive  examinations,  taking  the
nitial  staging  as  the  reference.  According  to  the  RECIST
.1  criteria  [18], monitoring  lymph  node  targets  uses  mea-
urement  of  the  shortest  diameter  of  an  adenomegaly  and
onitoring  visceral  targets  measures  the  longest  diameter
f  the  lesion.  At  the  most,  two  lymph  node  targets  and  two
argets  per  organ  need  to  be  included  in  this  monitoring
and  up  to  5  targets  in  total).  Changes  in  the  sum  of  the
iameters  determine  the  response  to  treatment.  A  reduc-
ion  of  at  least  30%  indicates  a  partial  or  total  response  and
n  increase  of  at  least  20%  shows  progression.  In  addition,
he  appearance  of  a  new  lesion  is  a  major  factor  indicating
rogression.
With  its  high  spatial  resolution  and  its  anatomical  pre-
ision,  the  chest/abdomen/pelvis  CT  scan  is  the  standard
xamination  for  analysing  the  response  of  metastases  of
esticular  cancer  to  treatment  [3,4,19,20]. Monitoring
s  focused  in  the  majority  of  cases  on  retroperitoneal
ymph  node  masses  (Figs.  3—5)  and/or  on  secondary  lung
odules.  If  injection  of  an  iodinated  contrast  agent  is
ontraindicated,  an  abdominopelvic  MRI  with  a  gadolinium
njection  can  be  proposed  to  monitor  abdominal  targets,
nd  a  chest  CT  scan  without  an  injection  of  contrast  agent
o  monitor  pulmonary  targets.  Current  recommendations
f  the  French  Association  of  Urology  (AFU)  advocate  a
hest/abdomen/pelvis  CT  scan  4  weeks  after  the  end  of
hemotherapy.  In  major  chemotherapy  (three  to  four  BEP
ourses),  a  CT  scan  after  two  courses  is  optional  [21].
After  chemotherapy,  a  residual  nodal  mass  may  remain
Figs.  4  and  5).  This  should  be  measured  on  the  CT  scan
o  decide  whether  to  pursue  additional  treatment  (salvage
hemotherapy  or  surgery)  or  provide  monitoring.  The  deci-
ion  to  surgically  remove  a  residual  mass  depends  on  the
eminomatous  or  non-seminomatous  nature  of  the  original
umour  and  the  size  of  the  residual  mass  (long  axis).  The  rule
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Figure 3. Complete response of an adenomegaly of the left spermatic cord in a left testicular non-seminomatous tumour treated by BEP
chemotherapy: a: initial assessmentBEPchest/abdomen/pelvis CT scan with injection of contrast agent: abdominal slice passing through the
renal pedicles: satellite adenomegaly of the left renal vein (arrow); b: re-evaluation after three courses of BEPBEPchest/abdomen/pelvis
CT scan with injection of contrast agent: abdominal slice passing through the renal pedicles: complete disappearance of the adenomegaly
(arrow).
Figure 4. Residual mass of less than 3 cm of a right non-seminomatous tumour after BEP chemotherapy: a: initial assess-
ment — chest/abdomen/pelvis CT scan with injection of contrast agent: abdominal slice passing through the renal pedicles:
interaortocaval adenomegaly of 3 cm (arrow) corresponding to a regional lymph node extension; b: re-evaluation after three courses of
BEP —chest/abdomen/pelvis CT scan with injection of contrast agent: persistence of a retroperitoneal adenomegaly measuring less than
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s  to  propose  systematic  surgical  resection  of  residual  masses
ith  a  long  axis  of  at  least  3  cm  [22]. Since  morbidity  from
uch  a  procedure  is  not  negligible,  the  fundamental  question
oncerns  the  vitality  and  severity  of  these  residual  masses,
nd  since  the  end  of  treatment  CT  scan  cannot  answer  this
uestion,  several  studies  have  evaluated  18FDG  PET  in  this
ndication  [23—28]. Some  have  concluded  that  the  absence
f  ﬁxation  of  a  mass  of  long  axis  greater  than  or  equal  to  3  cm
eems  to  indicate  the  absence  of  persistent  tumour  tissue
ithin  this  mass,  PET  reliability  not  apparently  being  so  good
or  masses  of  less  than  3  cm.  Other  authors  consider  that
here  are  false-positive  ﬁxations  of  residual  masses  corre-
ponding  not  to  tumour  tissue  but  to  inﬂammation,  necrosis
r  ﬁbrosis.  Regarding  the  risk  of  progression  to  a  mature
eratoma  (especially  for  non-seminomatous  tumours),  some
uthors  have  concluded  that  PET  could  not  differentiate  a
3
o
t
rature  teratoma  from  healing  ﬁbrosis,  or  necrosis.  PET  thus
as  no  clear  indication  in  monitoring  the  residual  masses  of
esticular  cancer.  Interpretation  seems  to  be  problematic
ven,  in  non-seminomatous  tumours.  The  current  ﬁndings  of
he  AFU,  however,  insist  on  the  fact  that  18FDG  PET  is  use-
ul  for  reassessing  metastatic  seminomatous  tumours  with
esidual  masses  4  to  6  weeks  after  chemotherapy,  in  order
o  choose  between  simply  monitoring  or  treating  them  [21].
wo  different  situations  must  be  deﬁned  depending  on  the
ize  of  the  residual  masses  (±3  cm).  In  the  case  of  a  mass
ess  than  3  cm,  careful  monitoring  is  recommended.  PET  is
ptional  because  it  is  non-speciﬁc.  If  the  mass  is  greater  than cm,  a  PET  scan  is  recommended  to  assess  the  presence
f  metabolic  activity  providing  evidence  of  active  tumour
issue.  Retroperitoneal  lymph  node  dissection  (unilateral)  is
ecommended  especially  if  the  mass  is  ﬁxed  in  the  PET  scan.
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Figure 5. Residual mass of more than 3 cm of a right non-seminomatous tumour after BEP chemotherapy: a: initial assess-
ment — chest/abdomen/pelvis CT scan with injection of contrast agent: abdominal slice passing through the renal pedicles: very large
retroperitoneal nodal mass (arrows); b: initial assessment — chest/abdomen/pelvis CT scan with injection of contrast agent: abdominal
slice through the perineum: right testicular mass (arrow); c: re-evaluation after four courses of BEP — chest/abdomen/pelvis CT scan with
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Imaging examinations to be performed in
post-treatment monitoring of testicular
cancer
As  with  any  type  of  cancer,  the  monitoring  strategy  after
treatment  is  fundamental  for  early  detection  of  recurrence.
In  the  case  of  the  testis,  recurrence  mainly  occurs  in  the
retroperitoneal  lymph  nodes  and  the  common  iliac  chains
(60  to  97%  of  cases)  [19,29]  and  occurs  in  80%  of  cases  within
1  year  following  orchiectomy  and  in  90%,  within  2  years  [30].
Late  recurrence  may  also  occur  after  10  years  or  more  [29].
The  two  important  factors  for  recurrence  seem  to  be  the
tumour  being  initially  greater  than  or  equal  to  4  cm  in  size
and  invasion  of  the  rete  testis  [29,31].
A  special  feature  of  testicular  cancer  is  the  ability  to  treat
early  recurrence  with  a  very  high  survival  rate  after  treat-
ment  (98%).  This  makes  monitoring  a  real  therapeutic  option
for  cancers  with  a  good  prognosis  and  can,  in  certain  circum-
stances,  avoid  excessive  initial  treatment.  This  monitoring
is  however  demanding  and  should  be  reserved  for  compliant,
lucid  patients  [3,4].
t
c
p
t long axis greater than 3 cm (arrows).
Optimal  monitoring  uses  CT  scans  covering  the  thorax,
bdomen  and  pelvis  [3—5]. The  frequency  of  these  scans  is
ery  variable,  depending  on  whether  the  tumour  is  semi-
omatous  or  non-seminomatous,  on  staging  and  the  initial
reatment.  It  can  be  very  demanding.  For  example,  in  a
atient  with  a  non-seminomatous  tumour  with  a  good  prog-
osis  (pT1  N0  M0),  a  CT  scan  is  currently  recommended  every
 months  during  the  ﬁrst  year  and  then  every  4  months  in
he  second  year  and  every  6  months  for  the  three  following
ears  [3—5]. This  large  number  of  scans  poses  the  problem  of
he  cumulative  X-ray  dose  for  the  often  very  young  patients.
n  an  attempt  to  reduce  this  dose,  a  study  reported  the  pos-
ibility,  when  monitoring  tumours  with  a  good  prognosis,  of
erforming  just  a  chest  X-ray  with  an  abdominopelvic  scan
17,32].  Another  study  prospectively  followed  two  groups  of
atients  with  non-seminomatous  tumours  with  a  good  prog-
osis:  one  group  had  ﬁve  chest/abdomen/pelvis  monitoring
cans  at  3,  6,  9,  12  and  24  months  after  orchiectomy  and
he  other  had  two  CT  scans  at  3  and  12  months.  This  arti-
le  found  that  there  was  no  greater  beneﬁt  in  the  group  of
atients  who  had  ﬁve  CT  scans  over  the  group  who  had  only
wo  [33].
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An  abdominopelvic  MRI  is  only  indicated  in  patients  with
 contraindication  for  the  injection  of  an  iodinated  con-
rast  agent  and  in  association  with  a  CT  scan  of  the  chest
ithout  injection.  The  frequency  of  these  two  examina-
ions  is  the  same  as  for  the  chest/abdomen/pelvis  scans
3—5].
Systematically  performing  a  PET  scan  for  monitoring  tes-
icular  carcinoma  is  not  recommended  at  present.  One  paper
as  however  stressed  its  usefulness  in  patients  with  elevated
erum  markers  unexplained  by  the  chest/abdomen/pelvis
can  [26].
It  is  recommended  that  the  remaining  testicle  should
e  monitored,  with  regular  self-examination  and  an  annual
ltrasound  examination  [3—5].
onclusion
or  diagnosing  a  testicular  mass,  echography  is  the  prime
rst-line  examination  to  undertake  in  addition  to  the  clinical
xamination.  The  diagnosis  of  cancer  and  the  degree  of  local
nvolvement  is  provided  by  surgical  removal  of  the  testis
inguinal  orchiectomy).  Lymph  node  and  visceral  staging  is
chieved  by  a  chest/abdomen/pelvis  CT  scan.
Monitoring  during  treatment  and  post-treatment  follow-
p  rely  heavily  on  CT  scans,  leaving  only  very  few  indications
or  MRI  and  PET  scans.  This  poses  the  problem  of  the  dose
f  X-rays  delivered  to  often  young  patients  whose  prognosis
s  frequently  good.  Randomised  studies  must  be  performed
n  the  future  to  optimise  the  radiation  dose  delivered  to
atients  and  to  determine  the  most  effective  monitoring
ossible.
TAKE-HOME  MESSAGES
• The  initial  staging  of  testicular  cancer  should  use
the  TNM  classiﬁcation.  The  T  stage  is  determined
by  histopathological  analysis  of  the  orchiectomy
tissue,  and  the  N  and  M  stages  by  performing  a
chest/abdomen/pelvis  CT  scan.  Indications  for  MRI
are  limited  and  are  not  systematic.  18FDG  PET
currently  has  no  place  in  this  context.
• The  efﬁcacy  of  treatment  of  metastases  of
testicular  cancer  is  evaluated  by  performing  a
chest/abdomen/pelvis  CT  scan  at  the  end  of
chemotherapy.  18FDG  PET  may  be  indicated  for
analysing  the  viability  of  residual  nodal  masses  in
seminomatous  tumours.
• Post-treatment  monitoring  of  testicular  cancer
should  be  by  regular  chest/abdomen/pelvis  scans
during  the  ﬁrst  5  years.  The  frequency  of
examinations  depends  on  the  type  of  tumour,
the  initial  staging  and  the  treatment  given.  This
monitoring  should  not  ignore  the  remaining  testis
which  should  be  checked  by  the  patient  himself  and
annually  by  ultrasound.L.  Brunereau  et  al.
linical case
istory of the disease
his  44-year-old  man,  with  three  children,  consulted  on
3rd  March  2009  for  the  development,  over  several  months,
f  a  painless  enlargement  of  the  left  side  of  the  scrotum.
n  clinical  examination,  there  was  a  left  intrascrotal  mass
hich  was  hard  on  palpation.  Ultrasound  conﬁrmed  the  tes-
icular  origin  and  the  nature  of  the  tissue  of  the  lesion,  which
easured  approximately  6  cm  in  length.  Markers  taken  on
he  same  day  (beta  HCG,  alpha  foeto-protein)  were  normal.
Inguinal  orchiectomy  was  performed  on  25th  March  2009.
nalysis  of  the  resected  tissue  provided  a  diagnosis  of  simple
T2  stage  seminoma.
A  chest/abdomen/pelvis  (CAP)  CT  scan  was  performed  on
7th  March  2009.  This  showed  a sub-renal  retroperitoneal
odal  mass  encompassing  the  aorta  and  inferior  vena  cava
easuring  8  cm  in  diameter  (Fig.  6a).  There  was  also  left
upraclavicular  adenomegaly.
At  the  multidisciplinary  meeting  on  6th  April  2009,  it  was
ecided  to  give  four  courses  of  BEP  (bleomycin,  etoposide,
isplatin)  adjuvant  chemotherapy.
The  situation  was  monitored  on  9th  July  2009  by  a  CAP
can  after  the  four  courses  of  chemotherapy.  This  produced
he  conclusion  that  there  was  a  therapeutic  response  greater
han  50%  and  that  there  was  a  lymph  node  mass  of  4  cm
ersisting  in  the  retroperitoneum  (Fig.  6b).
An  18FDG  PET  scan  was  performed  on  17th  July  2009;  no
xation  of  this  mass  was  found  (Fig.  6c).
Lymph  node  dissection  was  performed  on  14th  August
009.  Examination  of  the  tissue  from  surgery  revealed  exclu-
ively  the  presence  of  necrotic  tissue.
uestions
.  After  the  initial  CAP  scan,  what  were  the  TNM  classiﬁca-
tion  N  and  M  stages  in  this  patient?
. Why  was  a  PET  scan  performed  in  this  context?
nswers
.  The  retroperitoneal  adenomegalies  were  “satellites”  of
the  spermatic  vessels.  They  were  regional  adenome-
galies  the  large  diameter  of  which  was  assessed  to  be
8  cm  (i.e.  greater  than  5  cm).  The  N  stage  was  there-
fore  N3.  The  left  supraclavicular  adenomegaly  could  not
be  considered  as  “regional”  and  should  not  therefore
be  included  in  the  N  stage,  but  in  an  M  stage.  The  M
stage  was  therefore  “M1”.  The  TNM  classiﬁcation  in  this
patient  was  therefore  pT2  N3  M1;
.  The  PET  scan  was  used  to  search  for  factors  indicating
active  tumour  tissue  in  the  residual  mass.  If  there  had
been  ﬁxation  of  this  mass,  the  high  probability  of  per-
sistent  tumour  activity  would  have  led  to  VIP  salvage
chemotherapy  (ifosfamide,  etoposide,  cisplatin).  The
lack  of  ﬁxation  was  a  determining  factor  for  deferring
this  salvage  chemotherapy.  Nevertheless,  lymph  node
dissection  was  performed,  because  the  large  axis  of  the
mass  was  greater  than  3  cm.
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Figure 6. a: initial assessment-chest/abdomen/pelvis CT: scan without injection of contrast agent; abdominal slice passing through the
renal pedicles: very large retroperitoneal mass of 8 cm corresponding to a regional lymph node extension (arrows); b: re-evaluation after 4
courses of BEP; chest/abdomen/pelvis CT scan with injection of contrast agent; abdominal slice passing through the renal pedicles: partial
easurresponse (50%) demonstrated by a retroperitoneal residual mass m
the residual retroperitoneal mass (cross).
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